

pFUSE-SEAP-mG1-Fc

Plasmid designed for the expression of a SEAP-Fc Fusion protein

Catalog code: pfuse-mg1sp

<https://www.invivogen.com/pfuse-seap-mg1-fc>

For research use only

Version 22H30-MM

PRODUCT INFORMATION

Contents

- 20 µg of pFUSE-SEAP-mG1-Fc plasmid provided as lyophilized DNA
- 1 ml of Zeocin® (100 mg/ml)

Storage and stability:

- Product is shipped at room temperature.
- Upon receipt, store lyophilized DNA at -20°C.
- Resuspended DNA should be stored at -20°C.
- Store Zeocin® at 4 °C or at -20 °C. The expiry date is specified on the product label.

Quality control:

- Plasmid construct has been confirmed by restriction analysis and sequencing.
- Plasmid DNA was purified by ion exchange chromatography and lyophilized.
- Expression of SEAP-mG3Fc was confirmed by using QUANTI-Blue™ Solution.
- SEAP-mG3Fc protein was purified using protein G affinity chromatography following manufacturer's protocol.

GENERAL PRODUCT USE

pFUSE-SEAP-Fc plasmids express a SEAP-Fc fusion protein generated by fusing the gene encoding for human secreted alkaline phosphatase (SEAP) and the Fc region of an immunoglobulin G (IgG).

pFUSE-SEAP-Fc plasmids yield high levels of Fc-Fusion proteins. The level of expression is usually in the µg/mL range. They can be transfected in a variety of mammalian cells, including myeloma cell lines, Chinese hamster ovary (CHO) cells, monkey COS cells and human embryonic kidney (HEK)293 cells. These cells are commonly used in protein purification systems.

SEAP-Fc fusion proteins are secreted and can be easily detected in the supernatant of pFUSE-SEAP-Fc-transfected cells by using QUANTI-Blue™ Solution, a SEAP detection medium.

WARNING: mlgG1-Fc has a very low affinity to Protein A and Protein G making it difficult to purify.

PLASMID FEATURES

- **hEF1-HTLV prom** is a composite promoter comprising the Elongation Factor-1 α (EF-1 α) core promoter¹ and the R segment and part of the U5 sequence (R-U5') of the Human T-Cell Leukemia Virus (HTLV) Type 1 Long Terminal Repeat². The EF-1 α promoter exhibits a strong activity and yields long lasting expression of a transgene *in vivo*. The R-U5' has been coupled to the EF-1 α core promoter to enhance stability of RNA.
- **SEAP-mlgG1-Fc** was generated by fusing the gene encoding for human SEAP with the Fc region of mouse IgG3. This region comprises the CH2 and CH3 domains of the IgG heavy chain and the hinge region. The hinge serves as a flexible spacer between the SEAP and Fc moieties, allowing each part of the molecule to function independently.
- **SV40 pAn**: The Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA³.
- **ori**: A minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.
- **CMV enh / hFerL prom**: This composite promoter combines the human cytomegalovirus immediate-early gene 1 enhancer and the core promoter of the human ferritin light chain gene. This ubiquitous promoter drives the expression of the Zeocin®-resistance gene in mammalian cells.
- **EM2KC** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*. EM2KC is located within an intron and is spliced out in mammalian cells.
- **Zeo**: Resistance to Zeocin® is conferred by the *Sh ble* gene from *Streptallosteichus hindustanus*. The same resistance gene confers selection in both mammalian cells and *E. coli*.
- **βGlo pAn**: The human beta-globin 3'UTR and polyadenylation sequence allows efficient arrest of the transgene transcription⁴.

1. Kim DW et al. 1990. Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. 91(2):217-23.

2. Takebe Y. et al. 1988. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol Cell Biol. 8(1):466-72.

3. Carswell S. & Alwine JC. 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. Mol Cell Biol. 9(10):4248-58.

4. Yu J. & Russell JE. 2001. Structural and functional analysis of an mRNP complex that mediates the high stability of human beta-globin mRNA. Mol Cell Biol. 21(17):5879-88.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Asia: +852 3622-3480

E-mail: info@invivogen.com

METHODS

Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H₂O. Store resuspended plasmid at -20°C.

Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 other commonly used laboratory *E. coli* strains, such as DH5α.

Zeocin® usage

This antibiotic can be used for *E. coli* at 25 µg/ml in liquid or solid media and at 50-200 µg/ml to select Zeocin®-resistant mammalian cells.

RELATED PRODUCTS

Product	Catalog Code
LyoVec™	lyec-12
QUANTI-Blue™ Solution	rep-qbs

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873


InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Asia: +852 3622-3480

E-mail: info@invivogen.com





SgfI (11)

1 GGATCTCGATCGTCCGGTCCCCGTCAAGTGGGAGAGCGCACATGCCACAGTCCCAGAAGTTGGGGGAGGGTCGGCAATTGAACGGGTGCCTA
 101 GAGAACGGTGGCGGGGTAAACTGGAAAGTGATTCGTACTGGCTCGCTTCCCAGGGTGGGGAGAACCGTATAAGTCAGTAGTCGC

201 GTGAACGTTCTTTCGCAACGGTTGCCAGAACACAGCTGAAGCTCGAGGGCTGCATCTCCTCACCGGCCCTACCTGAGGCC HindIII (246)
 301 GCCATCCACGCCGGTGAAGTCCCTGCCCTCCCGCTGGCTCTGAACCTCCGGCTAGTAAGTTAACGTCAGGTCAGACC
 401 GGGCTTGTCCGGCTCCCTGGAGCTACCTAGACTCAGCCGCTCTCACGCTTGCCTGACCCCTGCTCAACTCACGTCAGGTCAGACC

AgeI (553)**BspHI (576)**

501 TCTGTTCTCGCCGTTACAGATCCAAGCTGACCGGGCCTACCTGAGATCACGGGTCAGCTGAGGGAGCACATCATGATCTGGGCCCTGCATGCT
 601 GCTGCTGCTGCTGCTGGCTGAGGCTACAGCTCCCTGGCATCATCCCAGTTGAGGAGGAACCCGGACTCTGGAACCGGAGGCAGCCAG 1►Met I I eLeuGl y ProCysMet Le
 701 8►uLeuLeuLeuLeuLeuLeuGl y ArgLeuGl nLeuSerLeuGl l eI I eLeuProVal Gl uGl uAsnProAspPheTrpAsnArgGl uAl aAl aGl u 9►
 701 GCCTGGGTGCCGCAAGAGCTGCAAGCAGCCAAAGACCTCATCTCTGGCGATGGATGGGGTGTCTACGGTGACAGCTG 10►Al aLeuGl yAl aAl aLysLysLeuGl nProAl aGl nThr Al aAl aLysAsnLeu l eI I ePheLeuGl yAspGl yMet Gl yVal Ser Thr Val Thr Al aA BamHI (804)

801 CCAGGATCTAAAGGGCAGAAGAAGACAACACTGGGCTGAGATACTGGCTATGGACCGCTCCCATATGTTGGCTCTGTCAGAACACATACATGTT 75►I aArg I I eLeuGl yGl nLysLysAspLysLeuGl y ProGl uI I eLeuProLeuAl aMet AspArgPheProTyrVal Al aLeuSer LysThr TyrAsnVa 901 AGACAAACATGTGCCAGACAGTGGAGGCCACAGGCCACGGCTACCTGTGGGGCTCAAGGGCACTTCCAGACCATTGGCTTGAGTCAGCCGCCCTT 108►I AspLysHisVal ProAspSer Gl yAl aThr Al aThrAl aTyrLeuCysGl yVal LysGl yAsnPheGl nThr I I eGl yLeuSer Al aAl aAl aArgPhe 1001 AACAGTGAACACGACACGGCAACGAGTCATCTCGTGTGAATCGGGCAAGAACAGCAGGGAAAGTCAGTGGAGTGGTAACCAACACAGACTGC 142►AsnGl nCysAsnThr Thr ArgGl yAsnGl uVal I I eI eLeuMetAsnArgAl aLysLysLeuGl yLysSer Val Gl yVal Val Thr Thr ArgVal Gl 1101 AGACGCTGCCGCGCCGCACTGGCCACACGGCTGAACCTGGCACTGGTACTCGGACGCCAGCTGGCTGCCCTGGCCGCCAGGAGGGTGCCAGGA 175►I nHi sAl aSer ProAl aGl yThr TyrAl aHi sThr Val AsnArgAsnTrpTyrSerAspAl aAspVal ProAl aSer Al aArgGl nGl uGl yCysGl nAs 1201 CATGCTACGCAGCTCATCTAACATGGACATTGATGTATGCTGGGGAGGCCAGAAGTACATGTTGCATGGAAACCCAGACCCCTGAGTACCA 208►pI I eAl aThr Gl I eLeuAsnMetAspI I eAspVal I I eLeuGl yGl yI yRglysTyrMetPheArgMetGl yI eLeuProAspProGl uTyrPro 1301 GATGACTACAGCCAAGGTGGGACAGGCTGGACGGGAGAATCTGGCTGGAGAATGGCTGGCAGGGCCAGGGTGGCTATGTGTAACCGCACTG 242►AspAspTyrSer Gl nGl yGl yThr ArgLeuAspGl yLysAsnLeuVal Gl nGl uTrpLeuAl aLysArgGl nGl I aI aArgTyrVal I TrpAsnArgThr G 1401 AGCTCATGCAGGCTTCCCTGGACCCTGGCTGTGACCCATCTCATGGCTCTTTGAGCCTGGAGACATGAAATACGAGATCCACCGAGACTCCACACTGGA 275►I uLeuMetGl nAl aSer LeuAspProSer Val Thr Hi sLeuMetGl yLeuProGl uProGl yAspMetLysTyrGl I I eHi sArgAspSer Thr LeuAs 1501 CCCCTCCCTGATGGAGATCAGAGGCTGCCCTGGCTGTGACGGAGACCCCCGGGCTTCTCTCTGTGAGGGTGGTCGCATGCACCAACGGT 308►pProSer LeuMetGl uMetThr Gl uAl aAl aLeuArgLeuSer ArgAsnProArgGl yPheLeuPheVal Gl uGl yGl yArgI I eAspHi sGl y 1601 CATCACAAAGCAGGGCTTACCGGGCACTGACTGAGACGATCATGTTGACGCCATTGAGAGGGGGCCAGCTCACCGAGGAGGACACGCTGA 342►Hi sHi sGl uSer ArgAl aTyrArgAl aLeuThr Gl uThr I I eI eLeuMetPheAspAspAl aI I eGl uArgAl aGl yGl nLeuThr Ser Gl uGl uAspThr LeuS 1701 GCCTCGTCACTGCCGACCACTCCACGTCTCTCTCGAGGGCTACCCCTGCGAGGGAGCTCATCTCGGGCTGGCCCTGGCAAGGCCGGGAGC 375►er LeuVal I Thr Al aAspHi sSer Hi sVal PheSer PheGl yGl yTyrProLeuArgGl ySer Ser I I ePheGl yLeuAl aProGl yLysAl aArgAspAr

StuI (1805)

EcoI47I (1805)

1801 GAAGGCCTACAGGCCCTCTATACGGAAACGGTCCAGGTATGTGCTCAAGGAGGGCCCGGATGTTACCGAGAGCGAGGCGGGAGCCCGAG 408►gLysAl aTyrThr Val LeuLeuTyrGl yAsnGl yProGl yTyrVal LeuLysAspGl yAl aArgProAspVal Thr Gl uSer Gl I ySer ProGl u 1901 TATCGGCACTGAGTCAGCAGTGGCCCTGGACGAAGAGACCCACGGCAGGGAGCTGGCGGTGTCGCGCGCGCCCGCAGCGCACCTGGTCACGGC 442►TyrArgGl nGl nSerAl aVal I ProLeuAspGl uGl uThr Hi sAl aGl yGl uAspVal Al aVal PheAl aArgGl yProGl nAl aHi sLeuVal Hi sGl y 2001 TGCAAGGAGCAGACCTTATAGCCGACGCTATGGCTTCGGCCCTGGAGCCCTACACCGCCCTGCGACCTGGGCCCGCCGACCCACCGAGC 475►al Gl nGl uGl nThr PheI I eAl aHi sVal MetAl aPheAl aAl aCysLeuGl uProTyrThr Al aCysAspLeuAl aProProAl aGl yThr ThrAspAl

BglII (2138)**BsrGI (2162)**

2101 CGCGCACCCGGGGCGTCCCGTCAAGCCTGATAGATCTGGTTGAAGCCTGCATATGTCAGTCCCAGAAGTATCATCTGTCATCTTCCC 508►aAl aHi sProGl yArgSer ArgSer LysArgLeuAspArgSer Gl yCysLysProCysI I eCysThr Val I ProGl uVal Ser Ser Val PheI I ePhePro 1►GlyCysLysProCysI I eCysThr Val I ProGl uVal Ser Ser Val PheI I ePhePro

BbrPI (2247)

2201 CCAAAGCCAAGGATGTGTCACCATTACTCTGACTCTAACGGTCACGTGTTGGTAGACATCAGCAAGGATGATCCGAGGTCCAGTCTAGCTGGT 542►ProLysProLysAspValLeuThr I I eLeuLeuThr ProLysVal Thr CysVal Val I Val AspI I eSer LysAspAspProGl uVal Gl nPheSer TrpP 20►ProLysProLysAspValLeuThr I I eLeuLeuThr ProLysVal Thr CysVal Val I Val AspI I eSer LysAspAspProGl uVal Gl nPheSer TrpP 2301 TTGTAGATGTTGGAGGTGCACAGCTCAGCGCAACCCGGGAGGAGCAGTCAACAGCACTTCCGCTCAGTCAGTGAACCTTCCATCATGCACCA 575►heValAspVal Gl uVal Hi sThr Al aGl nThr Gl nProArgGl uGl uGl nPheAsnSer Thr PheArgSer Val Ser Gl uLeuProl I eMetHi sGl 53►heValAspAspVal Gl uVal Hi sThr Al aGl nThr Gl nProArgGl uGl uGl nPheAsnSer Thr PheArgSer Val Ser Gl uLeuProl I eMetHi sGl 2401 GGACTGGCTCAATGCCAAGGAGTCAATCAGGGCTACAGTGGCTCCATGGCCCGCCATGGAGAAAACCATCTCCAAAAGGCAGACCGAG 608►nAspTrpLeuAsnGl yLysGl uPheLysCysArgValAsnSerAl aAl aPheP roAl aProl I eGl uLysThr I I eSer LysThr LysGl yArgProLys 86►nAspTrpLeuAsnGl yLysGl uPheLysCysArgValAsnSerAl aAl aPheP roAl aProl I eGl uLysThr I I eSer LysThr LysGl yArgProLys

BsrGI (2511)

2501 GCTCACAGGTACACCATCCACCTCCACCGAGATGGCAAGGATAAAGTCAGTCTGACCTGCATGATAACAGACTCTCCCTGAAGACATTA 642►Al aProGl nVal I TyrThr I I eProProProLysGl uGl nMetAl aLysAspLysVal Ser LeuThr CysMet I I eThrAspPhePheProGl uAspI I eT 120►Al aProGl nVal I TyrThr I I eProProProLysGl uGl nMetAl aLysAspLysVal Ser LeuThr CysMet I I eThrAspPhePheProGl uAspI I eT 2601 CTGTGGAGTGGCAGTGGATGGCAGCGGGAGGAACTACAAGACACTCAGCCCATCATGGACACAGATGGCTCTACTCGTCTACAGCAAGCTAA 675►hr Val Gl uTrpGl nTrpAsnGl yGl nProAl aGl uAsnTyrLysAsnThr Gl nProl I eMetAspThrAspGl ySer TyrPheVal TyrSer LysLeuAs 153►hr Val Gl uTrpGl nTrpAsnGl yGl nProAl aGl uAsnTyrLysAsnThr Gl nProl I eMetAspThrAspGl ySer TyrPheVal TyrSer LysLeuAs 2701 TGTGCAAGAGCAACTGGGGCAGGAAACTTTCACCTGCTGTGTTACATGGGGCTGCACACCATACTGAGAAGAGCTCTCCACT 708►nVal Gl nLysSerAsnTrpGl uAl aGl yAsnThr PheThr CysSer Val LeuHi sGl yLeuHi sAsnHi sHi sThr Gl uLysSer LeuSer Hi sSer 186►nVal Gl nLysSerAsnTrpGl uAl aGl yAsnThr PheThr CysSer Val LeuHi sGl yLeuHi sAsnHi sHi sThr Gl uLysSer LeuSer Hi sSer

NheI (2823)

2801 CCTGGTAAATGATCCAGTCAGCTGGCCAGACATGATAAGATAACATTGATGAGTTGGACAAACCAACTAGAATGCAGTAAAAAAATGCTT 742►ProGl yLys*** 220►ProGl yLys***

HpaI (2963)

2901 ATTTGTGAAATTGTGATGCTATTGCTTATTGTAACCATATAAGCTGCAATAAACAAAGTTAACACAACATTGATTTCATTCTTTATGTTCAAGTC

AseI (3060)

XmnI (3061)

3001 AGGGGGAGGTGGAGGTTTTAAAGCAAGTAAACCTCTACAAATGTTGATGGAATTAACTCTAAACATAGCAAAACTTAACCTCAA

3101 TCAAGCCTACTTGAATCTTTCTGAGGGATGAATAAGGCATAGGCATAGGGCTTGTCCAATGTGATTAGCTGTTGCAGCCACCTCTTC
 3201 ATGGAGTTAAAGATATAGTGTATTTCCAAGGTTGAACTAGCTCTTCAATTCTTAAATGCACTGACCTCCACATCCCTTTAGTAAA

Swal (3317)

3301 ATATTCAAGAAATAATTAAATACATCATTGCAATGAAAATAAATGTTTTATTAGGCAGAACATCCAGATGCTCAAGGCCCTCATATAATCCCCCAGTT
 3401 AGTAGTTGGACTTAGGAAACAAAGGAACTTAAAGAACCTTAATAGAAATTGGACAGCAAGAACGAGCTTCTAGCTTATCCTAGTCCTGCTCTGCCCCAACAGT
 3501 GCACCGAGTTGCCGGGGTCGCCAGGGCGAACCTCCGCCACGGCTGCTGCCATCTGGCATGGCTATGCCGGCCCGAGGGCTCCGGAAAGTTCG
 116 sVal CysAsnGl yAlaProAspArgLeuAl aPheGl uArgGl yTrpProGl nGl uGl y l eGl uThr MetAl aProGl ySerAl aAspArgPheAsnThr
 3601 GGACACGACCTCCGACCCTCGCTCACAGCTGCTCCAGGCCGCGCACCCACCCAGGCCAGGGTGTGTCGGACCCACCTGGCTCTGGACCCGCGCTG
 83 Ser Val Val Gl uSer TrpGl uAla TyrLeuGl uAspLeuGl yArgVal TrpVal TrpAl aLeuThr AsnAspProVal Val Gl nAspGl nVal Al aSer I

SgrAI (3730)

3701 ATGAAACAGGGTCACGTCGTCGGACACACCGGGAAAGTCGTCCTCCACGAAGTCCCAGGAGAACCCAGGCCGCTGGTCCAGAACACTGACCGCTCCGG
 49 LePheLeuThr Val AspAspArgVal Val Gl yAlaPheAspAspGl uVal PheAspArgSer PheGl yLeuArgAspThr TrpPheGl uVal Al aGl yAl
 3801 CGACGTCGCCGCGGTGAGCACGGCACTGGTCACTTGGCATGATGGCTCTCctgtcaggagggaaagagaagaaggtagtacaattCT
 16 aVal AspArgAl aThr LeuVal ProVal Al aSer Thr LeuLysAl aMet

Asel (3944)

3901 ATAGTGAGTTGATTATACTATGCAAGATACTATGCCAATGATTAATTGTCAAACTAGGGCTGCAGggttcatagtgcactttcctgcaactggcca

HindIII (4070)

4001 tctcctgcccaccccccaggcatagacagtcaagtactacCAAACTCACAGGAGGGAGAACGGCAGAGCTTGAGACAGACCCGGGGACCGCCGAA

StuI (4172)
Eco147I (4172)

4101 CTGCGAGGGGACGTGGCTAGGGCGCTCTTTATGGTGCGCCGGCTCGAGGGCAGGGCCTAGGGCCATCTGGCTGGCAGGGAG

BspEI (4228)

4201 GCGGGGCCGAAGGCCGTGCGTACCAATCCGGACATAGGAGTCTAGCCCCCGCCCAAAGCAAGGGGAAGTCACGCCCTGTAGGCCAGCGTGT

SpeI (4335)

4301 TGTGAAATGGGGCTTGGGGGTTGGGGCCTGACTAGTCAAAACAAACTCCATTGACGTCAATGGGTGGAGACTGGAAATCCCGTAGTCAAAC

SnaBI (4465)

4401 CGCTATCACGCCATTGATGACTGCAAACCCGATCATCATGTAATAGCGATGACTAATACGTAGATGACTGCAAGTAGGAAAGTCCATAAGG
 4501 TCATGTAATGGCATAATGCCAGGGGGCATTACCGTCAATTGACGTCAATAGGGGCGTACTTGGCATATGATACTTGATGACTGCCAAGTGGC
 4601 AGTTACCGTAAATACTCCACCCATTGACGTCAATGGAAAGTCCATTGGCGTTACTATGGAACATACGTATTGACGTCAATGGCGGGGTCG

PacI (4758)

4701 TTGGCGGTAGCCAGGCCGGCATTACCGTAAGTTATGTAACGCCCTGAGGTTAAAGAACATGTGAGCAAAGGCCAGCAAAGGCCAGGAACCG
 4801 TAAAAAGGCCGTTGCTGGCTTTCCATAGGCTCCGCCCTGACGAGCATCACAAATCGACGCTCAAGTCAGAGGTGGCAAACCCGACAGGA

SdaI (4751)

4901 CTATAAAAGATACCGAGCGTTCCCTGGAAGCTCCCTGCGCTCTCTGTTCCGACCCCTGCCCTACCGGATACCTGTCGCCCTTCCCTCGG
 5001 GAAGCGTGGCGTTCTCATAGCTACGCTGAGGTATCTCAGTCCGGTAGGTCGTTGCTCAAGCTGGCTGTGCAAGCACCCCCGTTCA
 5101 CGACCGCTGCCCTATCCGTAACATCGCTTGAAGACACGACTTACGCCACTGGCAGCAGCCACTGTAACAGGATTAGCAGA
 5201 GCGAGGTATGAGGGGTGCTACAGAGTTGAAGTGGCTAACACGGCTACAGAAGAACAGTATTGGTATCTGCGCTGCTGAAGCCAG
 5301 TTACCTCGAAAAAGAGTTGAGCTTGTATCCGCAAACAAACCCACCGCTGGTAGCGTGGTTTTGTTGCAAGCAGATTACGCGCAGAAA

PacI (5498)

5401 AAAAGGATCTCAAGAAGATCCTTGATCTTCTACGGGTCTGACGCTAGTGGAAACAAACTCACGTTAAGGGATTTGGTATGGCTAGTTAATTA

Swal (5506) NotI (5514)

5501 ACATTTAAATCAGGGCGCAATAAAATATCTTATTTCAATTACATCTGTTGGTTTTGTGAATCGTAACATAACATACGCTCTCCATCAAA
 5601 CAAAACGAAACAAACAAACTAGCAAAATAGGCTGCCAGTGCAGTGCAAGTCAGGTGCCAGAACATTCTCTATCGAA